Prosecution Insights
Last updated: November 04, 2026
Application No. 17/910,968

DELIVERY OF GENE EXPRESSION MODULATING AGENTS FOR THERAPY AGAINST CANCER AND VIRAL INFECTION

Final Rejection §103§112
Filed
Sep 12, 2022
Priority
Mar 10, 2020 — provisional 62/987,483 +1 more
Examiner
POLIAKOVA-GEORGAN, EKATERINA
Art Unit
1637
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Jonhoi Smith
OA Round
2 (Final)
64%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
82%
With Interview

Examiner Intelligence

Grants 64% of resolved cases
64%
Career Allowance Rate
440 granted / 690 resolved
+3.8% vs TC avg
Strong +18% interview lift
Without
With
+18.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 7m
Avg Prosecution
58 currently pending
Career history
763
Total Applications
across all art units

Statute-Specific Performance

§101
6.9%
-33.1% vs TC avg
§103
27.7%
-12.3% vs TC avg
§102
19.2%
-20.8% vs TC avg
§112
27.1%
-12.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 690 resolved cases

Office Action

§103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 5 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 5 depends on cancelled claim 2. For the purpose of examination it will be considered that claim 5 depends on claim 1, but appropriate correction is required. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 1, 3-6 is/are rejected under 35 U.S.C. 103 as being unpatentable over Sugaya (US 2012/0156226, June 2012, cited from IDS) and in further view of Gibbings et al (WO 2017/054085, April 2017, of record). Concerning claim 1 Sugaya teach methods of treating cancer by administering nanog modulating agent such as siRNA or ribozyme (see paragraph [0007]). Such methods are specifically targeted to cancer stem cells expressing nanog (see paragraph [0011]). By definition of siRNA it is a double-stranded RNA. Concerning claim 5 such siRNA downregulates expression of nanog (see paragraph [0065]). Limitation of claim 5 is expected to happen in the absence of evidence to the contrary upon practicing method of claim 1. Concerning claims 3-4 such therapy is administered before, during or after conventional therapy such as chemotherapy (see paragraph [0007]). Concerning claim 6 cancer to treat can be breast carcinoma (see paragraph [0006]). Sugaya do not teach loading stemness modulating agent such as siRNA into exosome. Gibbings teach producing exosomes comprising gene silencing nucleic acids (see lines 5- 10 on page 6), such silencing nucleic acid can be siRNA (see lines 17-20 on page 8). The exosomes can be used for delivery of the nucleic acids to cells (see lines 3-5 on page 6). It would have been obvious to one of the ordinary skill in the art before the effective filing date of the claimed invention to load exosomes as taught by Gibbings with siRNA taught by Sugaya for delivery to cancer cells. One of the ordinary skill in the art would be motivated to do so because Gibbings teach an effective method of siRNA delivery to cells using loading siRNA into exosomes. Response to Arguments Applicant's arguments filed 08/04/2026 have been fully considered but they are not persuasive. Previous 112 and 102 rejections are withdrawn in view of new amendments, arguments are moot. Concerning 103 rejection Applicant argues that Gibbings reference do not teach any stemness modulating agents for cancer treatment. In response such agent is taught by Sugaya reference. In response to applicant's arguments against the references individually, one cannot show nonobviousness by attacking references individually where the rejections are based on combinations of references. See In re Keller, 642 F.2d 413, 208 USPQ 871 (CCPA 1981); In re Merck & Co., 800 F.2d 1091, 231 USPQ 375 (Fed. Cir. 1986). Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to EKATERINA POLIAKOVA whose telephone number is (571)270-5257. The examiner can normally be reached Mon-Fri 8-5. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jennifer Dunston can be reached at (571)272-2916. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /EKATERINA POLIAKOVA-GEORGANTAS/Primary Examiner, Art Unit 1637
Read full office action

Prosecution Timeline

Sep 12, 2022
Application Filed
May 04, 2026
Non-Final Rejection mailed — §103, §112
Aug 04, 2026
Response Filed
Oct 13, 2026
Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12781274
Novel Replicase Cycling Reaction (RCR) and the Related RdRP-Binding Site Designs Thereof
3y 1m to grant Granted Nov 03, 2026
Patent 12781232
BACTERIAL CONTINUOUS EVOLUTION SYSTEM, ORTHOGONAL ERROR-PRONE DNA POLYMERASE, AND CONTINUOUS EVOLUTION METHOD
2y 11m to grant Granted Nov 03, 2026
Patent 12774310
POLYNUCLEOTIDES ENCODING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS
3y 5m to grant Granted Oct 27, 2026
Patent 12767946
OLIGONUCLEOTIDES FOR TISSUE SPECIFIC APOE MODULATION
6y 7m to grant Granted Oct 20, 2026
Patent 12735705
COMPOUND, METHOD AND PHARMACEUTICAL COMPOSITION FOR REGULATING EXPRESSION OF ATAXIN 3
3y 10m to grant Granted Sep 15, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
64%
Grant Probability
82%
With Interview (+18.3%)
2y 7m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 690 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month